LBS-008

RBP4 Pty Ltd · Phase 1 active Small molecule

At a glance

Generic name	LBS-008
Sponsor	RBP4 Pty Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease (PHASE2, PHASE3)
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy (PHASE3)
Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85 (PHASE1)
Safety and Tolerability Study of LBS-008 in Healthy Adult Subjects After Single and Multiple Doses (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LBS-008 CI brief — competitive landscape report
LBS-008 updates RSS · CI watch RSS
RBP4 Pty Ltd portfolio CI